Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Platycodin D3 is a triterpenoid saponin isolated from Platycodonis Radix (*Platycodon grandiflorum*), a plant widely utilized in traditional Chinese medicine. It demonstrates anti-inflammatory properties by reducing the secretion of inflammatory mediators such as nitric oxide (NO), prostaglandin E2 (PGE2), interleukin-6 (IL-6), and interleukin-17 (IL-17). Its mechanism of action involves inhibiting the protein expression of HSP90, TRAF6, phospho-NF-κB p65, and phospho-ERK1/2. Furthermore, Platycodin D3 mitigates chronic bronchitis inflammation through the inhibition of the TLR4/MyD88/NF-κB signaling pathway. When functionalized into biomimetic nanovaccines (PD3-SH-Lip), it acts as an immune stimulant, amplifying immune responses by activating NF-κB, MAPK, NOD-like, and TNF signaling pathways, leading to elevated levels of specific serum IgG and isotype titers, and robust CD4+ and CD8+ T cell immune responses, suggesting its potential for inhaled immunotherapy.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Platycodin D3.